Cancer Res Treat.  2003 Aug;35(4):323-329.

Prognostic Significance of KAI-1 and Survivin Expressions in Ovarian Epithelial Carcinomas

Affiliations
  • 1Department of Pathology, College of Medicine, Korea University, Seoul, Korea. jongchoi@kumc.or.kr

Abstract

PURPOSE
The purpose of this study was to evaluate the expressions of KAI-1 and survivin, and to investigate their correlation with the clinical stage and survival rate of patients with ovarian carcinomas.
MATERIALS AND METHODS
The expressions of survivin and KAI-1 were immunohistochemically determined in 54 serous and mucinous ovarian adenocarcinomas and borderline malignancy tumors. 10 of the 54 cases were also analyzed for the expressions of survivin and KAI-1 using western blot.
RESULTS
The down-regulation of the expression of KAI-1 was observed by immunohistochemical staining (IHC) in 53.7% of the ovarian cancers, and a negative reaction in 50% by the western blot analysis. From the IHC, the survivin expression was positive and strongly positive in 51.9 and 18% of the ovarian cancers, respectively. From the western blot analysis, 10% of the ovarian cancer showed positive reactions. The down- regulation of the KAI-1 expression was significantly correlated with the clinical stage (p=0.001) and disease free survival rate (p<0.001), but not with the histological type. The expression of survivin was not correlated with the clinical stage or histological type. However, the patients with a negative survivin expression had a significantly longer disease survival rate than those with a strong positive expression.
CONCLUSION
The down- and up-regulation of the KAI-1 and survivin, respectively, might be independent prognostic factors in human ovarian carcinomas.

Keyword

Ovary neoplasm; Survivin; KAI-1

MeSH Terms

Adenocarcinoma
Blotting, Western
Disease-Free Survival
Down-Regulation
Humans
Mucins
Ovarian Neoplasms
Survival Rate
Up-Regulation
Mucins
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr